These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2612540)

  • 1. Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.
    Bauer LA; Murray K; Horn JR; Opheim K; Olsen J
    Eur J Clin Pharmacol; 1989; 37(3):257-60. PubMed ID: 2612540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of single-dose and short-term oral nifedipine on indocyanine green clearance as assessed by spectrophotometry and high performance liquid chromatography.
    Soons PA; Kroon JM; Breimer DD
    J Clin Pharmacol; 1990 Aug; 30(8):693-8. PubMed ID: 2401748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of diltiazem on the pharmacokinetics of nifedipine.
    Ohashi K; Tateishi T; Sudo T; Sakamoto K; Toyosaki N; Hosoda S; Toyo-oka T; Sugimoto K; Kumagai Y; Ebihara A
    J Cardiovasc Pharmacol; 1990 Jan; 15(1):96-101. PubMed ID: 1688989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of nifedipine and captopril on liver blood flow in healthy subjects.
    Burggraaf J; Schoemaker RC; Kroon JM; Cohen AF
    Br J Clin Pharmacol; 1998 May; 45(5):447-51. PubMed ID: 9643616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic interaction between nifedipine and propranolol.
    Zylber-Katz E; Turetz-Abramovitch M; Koren G; Levy M
    Fundam Clin Pharmacol; 1988; 2(1):29-35. PubMed ID: 3371839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.
    Murdoch DL; Thomson GD; Thompson GG; Murray GD; Brodie MJ; McInnes GT
    Br J Clin Pharmacol; 1991 Mar; 31(3):323-32. PubMed ID: 2054272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green.
    Soons PA; De Boer A; Cohen AF; Breimer DD
    Br J Clin Pharmacol; 1991 Dec; 32(6):697-704. PubMed ID: 1768562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of physical exercise on the pharmacokinetics of propranolol.
    Arends BG; Böhm RO; van Kemenade JE; Rahn KH; van Baak MA
    Eur J Clin Pharmacol; 1986; 31(3):375-7. PubMed ID: 3792439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and pharmacokinetics of nifedipine administered by different routes in healthy volunteers.
    Palma-Aguirre JA; Rosas-Alcázar G; Rodríguez JM; León-Urrea F; Montoya-Cabrera MA
    Arch Invest Med (Mex); 1989; 20(2):129-35. PubMed ID: 2604495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative pharmacokinetics of different oral nifedipine preparations in healthy Brazilian volunteers.
    Vianna-Jorge R; Sudo RT; Melo PA; Suarez-Kurtz G
    Braz J Med Biol Res; 1992; 25(4):385-91. PubMed ID: 1342215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination].
    Sigusch H; Henschel L; Hoffmann A
    Gastroenterol J; 1991; 51(1):33-6. PubMed ID: 1910493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.
    Vinceneux P; Canal M; Domart Y; Roux A; Cascio B; Orofiamma B; Larribaud J; Flouvat B; Carbon C
    Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):153-8. PubMed ID: 2870990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic analyses of antihypertensive drugs, nifedipine and propranolol, in spontaneously hypertensive rats to investigate characteristics of effect and side effects.
    Kiriyama A; Honbo A; Nishimura A; Shibata N; Iga K
    Regul Toxicol Pharmacol; 2016 Apr; 76():21-9. PubMed ID: 26773344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine.
    Robertson DR; Waller DG; Renwick AG; George CF
    Br J Clin Pharmacol; 1988 Mar; 25(3):297-305. PubMed ID: 3358895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and hemodynamic effects of combined propranolol and nifedipine therapy versus propranolol alone in patients with angina pectoris.
    Braun S; Terdiman R; Berenfeld D; Laniado S
    Am Heart J; 1985 Mar; 109(3 Pt 1):478-85. PubMed ID: 3976473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.
    Langner B; Lemmer B
    Eur J Clin Pharmacol; 1988; 33(6):619-24. PubMed ID: 3366165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.
    van Harten J; van Brummelen P; Lodewijks MT; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1988 Mar; 43(3):332-41. PubMed ID: 3345623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Non-invasive regional and cardiac output determination in healthy volunteers. Predictive value].
    Thuillez C; Leroy JP; Loueslati H; Bellissant E; Giudicelli JF
    Arch Mal Coeur Vaiss; 1989 Jul; 82(7):1275-9. PubMed ID: 2510661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronopharmacokinetics and cardiovascular effects of nifedipine.
    Lemmer B; Nold G; Behne S; Kaiser R
    Chronobiol Int; 1991; 8(6):485-94. PubMed ID: 1799930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.